The dynamic nature of the kinome

被引:66
作者
Graves, Lee M. [1 ]
Duncan, James S. [1 ]
Whittle, Martin C. [1 ]
Johnson, Gary L. [1 ]
机构
[1] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA
基金
美国国家卫生研究院;
关键词
CHRONIC MYELOID-LEUKEMIA; RECEPTOR TYROSINE KINASES; ACQUIRED-RESISTANCE; CHEMICAL PROTEOMICS; CELLULAR TARGETS; PROTEIN-KINASES; MEK INHIBITORS; CANCER KINOME; BREAST-CANCER; HEMATOLOGIC MALIGNANCIES;
D O I
10.1042/BJ20121456
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recent advances in proteomics have facilitated the analysis of the kinome 'en masse'. What these studies have revealed is a surprisingly dynamic network of kinase responses to highly selective kinase inhibitors, thereby illustrating the complex biological responses to these small molecules. Moreover these studies have identified key transcription factors, such as c-Myc and FOXO (forkhead box O), that play pivotal roles in kinome reprogramming in cancer cells. Since many kinase inhibitors fail despite a high efficacy of blocking their intended targets, elucidating kinome changes at a more global level will be essential to understanding the mechanisms of kinase inhibitor pharmacology. The development of technologies to study the kinome, as well as examples of kinome resilience and reprogramming, will be discussed in the present review.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 98 条
[21]   A small molecule-kinase interaction map for clinical kinase inhibitors [J].
Fabian, MA ;
Biggs, WH ;
Treiber, DK ;
Atteridge, CE ;
Azimioara, MD ;
Benedetti, MG ;
Carter, TA ;
Ciceri, P ;
Edeen, PT ;
Floyd, M ;
Ford, JM ;
Galvin, M ;
Gerlach, JL ;
Grotzfeld, RM ;
Herrgard, S ;
Insko, DE ;
Insko, MA ;
Lai, AG ;
Lélias, JM ;
Mehta, SA ;
Milanov, ZV ;
Velasco, AM ;
Wodicka, LM ;
Patel, HK ;
Zarrinkar, PP ;
Lockhart, DJ .
NATURE BIOTECHNOLOGY, 2005, 23 (03) :329-336
[22]   The (un)targeted cancer kinome [J].
Fedorov, Oleg ;
Mueller, Susanne ;
Knapp, Stefan .
NATURE CHEMICAL BIOLOGY, 2010, 6 (03) :166-169
[23]   Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma [J].
Flaherty, Keith T. ;
Robert, Caroline ;
Hersey, Peter ;
Nathan, Paul ;
Garbe, Claus ;
Milhem, Mohammed ;
Demidov, Lev V. ;
Hassel, Jessica C. ;
Rutkowski, Piotr ;
Mohr, Peter ;
Dummer, Reinhard ;
Trefzer, Uwe ;
Larkin, James M. G. ;
Utikal, Jochen ;
Dreno, Brigitte ;
Nyakas, Marta ;
Middleton, Mark R. ;
Becker, Juergen C. ;
Casey, Michelle ;
Sherman, Laurie J. ;
Wu, Frank S. ;
Ouellet, Daniele ;
Martin, Anne-Marie ;
Patel, Kiran ;
Schadendorf, Dirk .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (02) :107-114
[24]   Inhibitors paradoxically prime kinases [J].
Frye, Stephen V. ;
Johnson, Gary L. .
NATURE CHEMICAL BIOLOGY, 2009, 5 (07) :448-449
[25]   Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling [J].
Godl, K ;
Gruss, OJ ;
Eickhoff, J ;
Wissing, J ;
Blencke, S ;
Weber, M ;
Degen, H ;
Brehmer, D ;
Orfi, L ;
Horváth, Z ;
Kéri, G ;
Müller, S ;
Cotten, M ;
Ullrich, A ;
Daub, H .
CANCER RESEARCH, 2005, 65 (15) :6919-6926
[26]   An efficient proteomics method to identify the cellular targets of protein kinase inhibitors [J].
Godl, K ;
Wissing, J ;
Kurtenbach, A ;
Habenberger, P ;
Blencke, S ;
Gutbrod, H ;
Salassidis, K ;
Stein-Gerlach, M ;
Missio, A ;
Cotten, M ;
Daub, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (26) :15434-15439
[27]   Targeting Multiple Kinase Pathways: A Change In Paradigm [J].
Gossage, Lucy ;
Eisen, Tim .
CLINICAL CANCER RESEARCH, 2010, 16 (07) :1973-1978
[28]   "Going KiNativ": Probing the Native Kinome [J].
Graves, Lee M. ;
Litchfield, David W. .
CHEMISTRY & BIOLOGY, 2011, 18 (06) :683-684
[29]   Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations [J].
Greger, James G. ;
Eastman, Stephen D. ;
Zhang, Vivian ;
Bleam, Maureen R. ;
Hughes, Ashley M. ;
Smitheman, Kimberly N. ;
Dickerson, Scott H. ;
Laquerre, Sylvie G. ;
Liu, Li ;
Gilmer, Tona M. .
MOLECULAR CANCER THERAPEUTICS, 2012, 11 (04) :909-920
[30]   New roles for the LKB1→AMPK pathway [J].
Hardie, DG .
CURRENT OPINION IN CELL BIOLOGY, 2005, 17 (02) :167-173